For a long time, economic evaluations including cost analysis studies were uncommon in medicine, especially in orthopaedic surgery. Because of the increasing importance of financial factors, the efficient use of available resources has become more important. In 2017, the United States spent 17.2% of its gross domestic product in the health care sector, much more than any other country (eg, Germany: 11.3%; Japan: 10.7%) and much more than in 2000, when only 12.5% of the United States gross domestic product was spent in the health care sector.^[@bibr44-2325967120917121]^

The purpose of economic evaluations is to analyze alternative courses of action (eg, different treatments) in terms of both their costs and consequences (eg, patient outcomes).^[@bibr15-2325967120917121]^ The aim should be to increase value for the patients, with "value" defined as the health outcome per dollar spent.^[@bibr48-2325967120917121]^ The outcome is not only the achieved health status but also the process of regeneration and the achievement of sustainable health. If a more expensive treatment method leads to faster regeneration and earlier return to work, then this method can still be cost-effective.

Cost analysis can be performed using different methods, with cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis being most common.^[@bibr4-2325967120917121],[@bibr15-2325967120917121]^ As a measure of outcome, the use of quality-adjusted life years (QALYs) has been widely established.^[@bibr4-2325967120917121],[@bibr50-2325967120917121]^ QALYs facilitate the comparison of different treatment options, and incremental cost analysis can be performed (incremental cost-effectiveness ratio \[ICER\]). QALYs are calculated using generic quality of health measurement tools such as the EuroQol 5 Dimensions index (EQ-5D) or Short Form--6 Dimensions (SF-6D).^[@bibr5-2325967120917121],[@bibr56-2325967120917121]^ However, better measurement tools for the "outcome" have not yet been established, and suitable instruments that are more specific than the EQ-5D/SF-6D but still allow comparisons between different diseases are still under development.^[@bibr40-2325967120917121],[@bibr49-2325967120917121]^ Investigators should study and report evidence-based results from validated, disease-specific, and patient-reported outcome measures as well as health-related quality of life measures.

By defining the threshold of what a QALY (1 year in perfect health, usually US\$50,000-\$100,000/QALY) may cost, resources can be better distributed among different treatment strategies.^[@bibr37-2325967120917121],[@bibr39-2325967120917121]^ For example, it would be more useful to support a therapy that increased quality of life by 2.0 QALYs for the cost of \$50,000 than a similar therapy that also cost \$50,000 but increased the QALY only by 1.0. For mathematical calculations, different models (eg, Markov, Monte Carlo) are used and various statistical methods applied to compensate for uncertainty (eg, probabilistic sensitivity analysis, 1- or 2-way sensitivity analysis) as well as the future inflation of costs (eg, discounting). See [Table 1](#table1-2325967120917121){ref-type="table"} for a brief explanation of key concepts.

###### 

Overview and Explanations of Abbreviations, Terms, and Concepts*^a^*

![](10.1177_2325967120917121-table1)

  ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cost-effective threshold             Value that a society is willing to pay for health. Used as a rough guide to help determine whether a particular investment constitutes a reasonable value. Varies from country to country. Referencing a threshold of US\$50,000/QALY has, in practice, implied adding new favorable interventions but without displacing any unfavorable interventions. An increase of the threshold from \$25,000 to \$100,000 results in more money needed in the health care system.
  Discounting                          Economic evaluation practice of weighting future gains and losses in health care less heavily than those in the present.
  EQ-5D                                Standardized instrument for measuring generic health status.
  ICER                                 Outline of the incremental cost associated with 1 additional unit of the measure of effect. ICER = Δ cost/Δ health gain (eg, life years, shoulder function).
  Markov model                         Used to show how a hypothetical cohort of patients moves between different health states over time. The model simulation ends when all patients in the cohort are "dead" to compare long-term health and cost outcomes.
  Monte Carlo simulation               Method for the calculation of cost-effectiveness ratios and uncertainties involved in the analysis. Includes the mean value and variance of cost-effectiveness ratio, probability distribution function, skewness, and cumulative frequency distribution.
  Probabilistic sensitivity analysis   Demonstrates the parameter uncertainty in a decision problem. Involves sampling parameters from their respective distributions (rather than simply using mean/median values).
  QHES                                 Validated questionnaire to assess the quality of economic studies with 16 criteria (maximum score = 100). Values of 80-100 points are generally attributed to high-quality studies, and studies \<50 points are considered not worthy of publication.
  QALY                                 Routinely used as a summary measure of health outcomes for economic evaluations, which incorporates the impact on both the quantity and the quality of life. QALY = T~1~Q~1~ -- T~0~Q~0~ (with "T" being survival year, "Q" being health status, "1" being perfect health status, and "0" being death).
  Sensitivity analysis                 Cost-effectiveness analysis is one of the main tools of economic evaluations. Every cost-effectiveness analysis is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis formalizes ways to measure and evaluate this uncertainty.
  SF-6D                                Evaluation tool of health status used in economics as a variable in the QALY calculation to determine the cost-effectiveness of a treatment.
  ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*^a^*EQ-5D, EuroQol 5 Dimensions; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; QHES, Quality of Health Economic Studies; SF-6D, Short Form--6 Dimensions.

Multiple cost analysis studies and reviews have been published in sports orthopaedics over the past years, especially focusing on anterior cruciate ligament reconstruction.^[@bibr41-2325967120917121],[@bibr53-2325967120917121]^ In shoulder surgery, cost analysis studies have rarely been performed or are of lower quality, as stated in a review from 2012 that included literature before 2010.^[@bibr27-2325967120917121]^ Therefore, the aim of this work was to analyze the current state of cost-effectiveness analyses in shoulder surgery since 2010.

Methods {#section1-2325967120917121}
=======

This systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.^[@bibr36-2325967120917121]^ A systematic electronic search of the PubMed database was conducted in November 2019 to identify clinical studies investigating cost analysis in shoulder surgery. The following search terms were used in all fields: (cost analysis AND shoulder). Studies were limited to articles published after December 2009. In addition to the electronic search, the reference lists of all included articles were manually searched for additional relevant articles.

For the purpose of this systematic review, only clinical studies that specifically investigated full economic analyses (defined by comparing ≥2 alternative treatments and including both costs and effects) were included. Additional inclusion criteria were as follows: English-language studies, studies published online, or studies in print in a peer-reviewed journal. The exclusion criteria were as follows: narrative or systematic reviews, meeting abstracts, and proceedings.

The titles and abstracts of all articles were screened for relevance according to the inclusion and exclusion criteria. If no abstract was available, the full-text article was obtained to assess the relevance of the study. The full text was obtained and subsequently reviewed for possible inclusion in the systematic review for all articles that were not excluded during the initial screening process.

Quality Assessment {#section2-2325967120917121}
------------------

All included studies were assessed and assigned a level of evidence (level 1-5) according to the Oxford Centre for Evidence-Based Medicine (OCEBM) criteria for economic studies.^[@bibr32-2325967120917121]^ Level 1 and 2 studies include complex computer simulation models (Monte Carlo simulation, Markov model) with inputs derived solely from level 1 or 2 studies.^[@bibr32-2325967120917121]^ Additionally, the Quality of Health Economic Studies (QHES) instrument was used to assess the quality of the included studies as used in other studies in orthopaedic surgery.^[@bibr41-2325967120917121],[@bibr43-2325967120917121]^ There were 2 authors (T.T. and C.L.) who independently performed the evaluation, and a consensus was reached by a discussion. The QHES instrument consists of 16 "yes" or "no" questions, with each question weighted between 1 and 9 points and a total score range from 0 to 100. Scores in the range of 80 to 100 are generally considered high quality, whereas scores below 50 are typically not deemed worthy of publication.^[@bibr43-2325967120917121]^

Results {#section3-2325967120917121}
=======

In the scope of this systematic literature review, 406 articles published after the end of 2009 were found that reported on cost analysis and the shoulder ([Figure 1](#fig1-2325967120917121){ref-type="fig"}). After the exclusion criteria were applied, 34 studies that performed full economic analyses were included ([Table 2](#table2-2325967120917121){ref-type="table"}). The detailed results are displayed in individual tables: 13 studies considered the topic of rotator cuff tears (RCTs) ([Table 3](#table3-2325967120917121){ref-type="table"}), 3 considered shoulder instability ([Appendix Table A1](#table5-2325967120917121){ref-type="table"}), 3 considered glenohumeral osteoarthritis ([Appendix Table A2](#table6-2325967120917121){ref-type="table"}), 4 considered proximal humeral fractures ([Appendix Table A3](#table7-2325967120917121){ref-type="table"}), 4 considered subacromial impingement ([Appendix Table A4](#table8-2325967120917121){ref-type="table"}), and 7 considered other shoulder conditions ([Appendix Table A5](#table9-2325967120917121){ref-type="table"}). The high-quality studies included in this systematic review show cost-effective therapeutic strategies.

![Flowchart of the search strategy in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.](10.1177_2325967120917121-fig1){#fig1-2325967120917121}

###### 

Characteristics of Included Studies*^a^*
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)                                                                                                                             Journal (Country)                                                      Primary Outcome                        Data Source                       Study Perspective            QALY Threshold           Methods                              Sensitivity Analysis                      Time Frame (Discounting)    Level of Evidence^[@bibr32-2325967120917121]^   QHES Score
  ----------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------- --------------------------------- ---------------------------- ------------------------ ------------------------------------ ----------------------------------------- --------------------------- ----------------------------------------------- ------------
  **Rotator cuff tear (n = 13)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

   Nicholson^[@bibr38-2325967120917121]^ (2019)                                                                                             *Bone Joint J* (UK)                                                    ICER                                   n = 92                            NHS                          £20,000                                                       Yes                                       No                          4                                               87

   Castagna^[@bibr7-2325967120917121]^ (2019)                                                                                               *Int Orthop* (Italy)                                                   ICER                                   Literature review and experts     Health care                  \$50,000                 Decision analytic model              1-/2-way                                  2 y (no information)        4                                               73

   Gyftopoulos^[@bibr19-2325967120917121]^ (2017)                                                                                           *J Shoulder Elbow Surg* (USA)                                          ICER                                   Literature review and experts     Health care                  \$100,000                Decision analytic model              1-/2-way                                  2 y (3%/y)                  3                                               99

   Dornan^[@bibr13-2325967120917121]^ (2017)                                                                                                *Arthroscopy* (USA)                                                    ICER                                   Literature review and experts     Health care                  \$50,000                 Markov decision model                1-/2-way                                  Lifetime (3%/y)             3                                               95

   Huang^[@bibr23-2325967120917121]^ (2017)                                                                                                 *J Bone Joint Surg Am* (Canada)                                        ICER                                   Literature review and experts     Health care                  \$50,000                 Decision analytic model              1-way, PSA                                2 y (5%/y)                  4                                               93

   Kang^[@bibr26-2325967120917121]^ (2017)                                                                                                  *Orthopedics* (USA)                                                    ICER                                   Literature review and experts     Health care                  \$50,000                 Markov decision model                1-/2-way                                  Lifetime (3%/y)             3                                               99

   Makhni^[@bibr30-2325967120917121]^ (2016)                                                                                                *Arthroscopy* (USA)                                                    ICER                                   Literature review and experts     Health care                  \$50,000 and\            Decision analytic model              1-/2-way                                  Lifetime (---)              3                                               99
                                                                                                                                                                                                                                                                                                                         \$100,000                                                                                                                                                                           

   Samuelson^[@bibr54-2325967120917121]^ (2016)                                                                                             *Arthroscopy* (USA)                                                    ICER                                   Literature review and experts     Health care                  \$50,000                 Markov decision model                1-way                                     10 y (3%/y)                 3                                               99

   Carr^[@bibr6-2325967120917121]^ (2015)                                                                                                   *Health Technol Assess* (UK)                                           ICER/OSS score                         n = 273                           Health care                  £20,000-£30,000          Trial                                Adjusting for covariates                  2 y (---)                   4                                               92

   Mather^[@bibr33-2325967120917121]^ (2013)                                                                                                *J Bone Joint Surg Am* (USA)                                           ICER                                   Literature review and experts     Society                      \$50,000                 Markov decision model                1-/2-/3-way, PSA                          Lifetime (3%/y)             2                                               99

   Renfree^[@bibr51-2325967120917121]^ (2013)                                                                                               *J Shoulder Elbow Surg* (USA)                                          Cost/QALY                              n = 30                            Health care                  \$50,000                 Trial                                No                                        2 y (3%/y)                  5                                               38

   Coe^[@bibr9-2325967120917121]^ (2012)                                                                                                    *J Shoulder Elbow Surg* (USA)                                          ICER                                   Literature review and experts     Society and payer            \$100,000                Markov decision model                1-way                                     Lifetime (3%/y)             3                                               96

   Genuario^[@bibr16-2325967120917121]^ (2012)                                                                                              *J Bone Joint Surg Am* (USA)                                           ICER                                   Literature review                 Society                      \$100,000                Decision analytic model              1-/2-way                                  Lifetime (3%/y)             3                                               99

  **Shoulder instability (n = 3)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

   Min^[@bibr35-2325967120917121]^ (2018)                                                                                                   *J Shoulder Elbow Surg* (USA)                                          ICER                                   Literature review/trial           Health care                  \<\$57,300               Markov decision model                Multivariate, PSA                         Lifetime (no information)   2                                               85

   Makhni^[@bibr29-2325967120917121]^ (2016)                                                                                                *Arthroscopy* (USA)                                                    ICER                                   Literature review and experts     Health care                  \$50,000 and \$100,000   Decision analytic model              1-/2-way                                  Lifetime (no information)   4                                               84

   Crall^[@bibr11-2325967120917121]^ (2012)                                                                                                 *Arthroscopy* (USA)                                                    Cost/QALY                              Literature review and experts     Payer                        \$25,000                 Markov decision model                Microsimulation, PSA                      15 y (5%/y)                 2                                               100

  **Osteoarthritis (n = 3)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

   Bhat^[@bibr3-2325967120917121]^ (2016)                                                                                                   *Clin Orthop Relat Res* (USA)                                          ICER                                   Literature review and experts     Health care                  \$50,000                 Markov decision model                1-way, PSA                                Lifetime (no information)   2                                               92

   Bachman^[@bibr2-2325967120917121]^ (2016)                                                                                                *World J Orthop* (USA)                                                 Cost/QALY                              n = 15 vs study with 224 THA      Health care                  \$30,000-\$50,000        Markov decision model                No                                        Lifetime (3%/y)             5                                               71

   Mather^[@bibr34-2325967120917121]^ (2010)                                                                                                *J Shoulder Elbow Surg* (USA)                                          ICER                                   Literature review and experts     Society                      \$50,000                 Markov decision model                Multivariate                              Lifetime (3%/y)             2                                               99

  **Proximal humeral fracture (n = 4)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

   Osterhoff^[@bibr45-2325967120917121]^ (2017)                                                                                             *Value Health* (Canada)                                                ICER                                   Literature review and experts     Health care (single payer)   Can\$50,000              Decision tree and Markov modeling    1-/2-way, PSA                             Lifetime (5%/y)             2                                               99

   Nwachukwu^[@bibr42-2325967120917121]^ (2016)                                                                                             *J Shoulder Elbow Surg* (USA)                                          ICER                                   Literature review and experts     US payers and hospitals      \$100,000                Markov decision model                Deterministic sensitivity analysis, PSA   Lifetime (3%/y)             2                                               99

   Corbacho^[@bibr10-2325967120917121]^ (2016)/Handoll^[@bibr20-2325967120917121]^ (2015)/Handoll^[@bibr21-2325967120917121]^ (2017)*^b^*   *Bone Joint J* (UK)/*Health Technol Assess* (UK)/*Bone Joint J* (UK)   Cost/QALY                              n = 250                           NHS                          £20,000-£30,000          Trial                                Complete case analysis                    2 y (3.5%/y)                4                                               92

  **Subacromial impingement (n = 4)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

   Rombach^[@bibr52-2325967120917121]^ (2019)                                                                                               *Bone Joint J* (UK)                                                    QALY/ICER                              n = 313                           Health care                  £20,000                  Trial                                Yes                                       12 mo (---)                 2                                               92

   Arias-Buria^[@bibr1-2325967120917121]^ (2018)                                                                                            *Pain Med* (Spain)                                                     QALY/ICER                              n = 50                            Society                      ---                      Trial                                1-way                                     ---                         5                                               89

   Marks^[@bibr31-2325967120917121]^ (2016)                                                                                                 *PLoS One* (Australia)                                                 SPADI score                            n = 64                            Health funder                AUD\$50,000              Trial                                1-way                                     12 wk (---)                 5                                               78

   Jowett^[@bibr25-2325967120917121]^ (2013)                                                                                                *Rheumatology (Oxford)* (UK)                                           ICER                                   n = 232                           Health care                  £20,000                  Trial                                Nonparametric bootstrapping               24 wk (---)                 5                                               87

  **Other (n = 7)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

   Sorensen^[@bibr57-2325967120917121]^ (2020)                                                                                              *J Shoulder Elbow Surg* (Denmark)                                      QALY/ICER                              Literature review and experts     Health sector                €34,000                  Decision analytic model              1-way                                     12 mo (---)                 1                                               84

   Gyftopoulos^[@bibr18-2325967120917121]^ (2018)                                                                                           *AJR Am J Roentgenol* (USA)                                            ICER                                   Literature review and experts     Health care                  \$100,000                Decision analytic model              1-/2-way, PSA                             6 mo (no information)       4                                               81

   Paoli^[@bibr46-2325967120917121]^ (2018)                                                                                                 *Arthroscopy* (USA)\                                                   QALY/ICER                              Literature review and experts     Society                      \$100,000                Decision tree and Markov modeling\   1-/2-way, PSA                             10 y (---)                  3                                               99

   Hatch^[@bibr22-2325967120917121]^ (2017)                                                                                                 *J Shoulder Elbow Surg* (USA)                                          Cost- effectiveness                    n = 16                            Health care                  No                       Breakeven analysis                   ---                                       ---                         4                                               51

   Scott^[@bibr55-2325967120917121]^ (2015)                                                                                                 *Orthop J Sports Med* (USA)                                            Cost/case because of adverse outcome   Literature review and experts     Society                      ---                      Decision analytic model              Monte Carlo simulation                    ---                         5                                               75

   Dattani^[@bibr12-2325967120917121]^ (2013)                                                                                               *Bone Joint J* (UK)                                                    Cost/QALY                              n = 100 and NHS reference costs   Health care                  £30,000                  Trial                                No                                        6 mo (---)                  5                                               57

   Pearson^[@bibr47-2325967120917121]^ (2010)                                                                                               *J Orthop Trauma* (Canada)                                             ICER                                   n = 132                           Health care                  \$50,000                 Trial                                Yes                                       25.8 y (3%/y)               3                                               99
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*^a^*ICER, incremental cost-effectiveness ratio; NHS, National Health Service; OSS, Oxford Shoulder Score; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; QHES, Quality of Health Economic Studies; SPADI, Shoulder Pain and Disability Index; THA, total hip arthroplasty; ---, no information provided.

*^b^*All 3 studies were related to the PROFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial. The two Handoll et al studies were considered a single study for the purposes of this review.

###### 

Economic Evaluations Concerning RCTs (n = 13)*^a^*

![](10.1177_2325967120917121-table3)

  Author (Year)                                    Purpose                                                                                                                         Groups                                                                                                      Results                                                                                                                                                                                                                                                                                                                                                                                                                             Conclusions
  ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nicholson^[@bibr38-2325967120917121]^ (2019)     Determine cost-effectiveness of arthroscopic RCR over 2-y period and if age adversely affects outcome/cost-effectiveness        \(1\) Arthroscopic RCR                                                                                      No significant difference between age \<65 or \>65 y regarding postoperative shoulder function or EQ-5D score; total mean cost per patient was £3646.94, and mean EQ-5D difference at 1 y was 0.2691, resulting in mean ICER of £13,552.36/QALY; smokers had ICER that was 4 times more expensive                                                                                                                                   Arthroscopic RCR resulted in excellent patient satisfaction and cost-effectiveness, regardless of age
  Castagna^[@bibr7-2325967120917121]^ (2019)       Determine cost-effectiveness of treatment for irreparable RCTs                                                                  \(1\) Subacromial spacer, (2) RCR, (3) TSA, (4) nonoperative treatment                                      Subacromial spacer cost less and increased effectiveness by 0.06 and 0.10 QALYs, respectively; nonoperative treatment least costly; subacromial spacer gained 0.05 QALYs for additional cost of €522 (ICER, €10,440/QALY)                                                                                                                                                                                                           Subacromial spacer likely to be safe, effective, and cost-effective option for massive irreparable RCTs
  Gyftopoulos^[@bibr19-2325967120917121]^ (2017)   Determine imaging strategies for full-thickness supraspinatus tears                                                             \(1\) MRI, (2) ultrasound, (3) ultrasound followed by MRI                                                   Ultrasound least costly strategy (\$1385); MRI most effective (1.332 QALYs; ICER, \$22,756/QALY)                                                                                                                                                                                                                                                                                                                                    Ultrasound most cost-effective strategy; MRI was preferred strategy based on cost-effectiveness criteria
  Dornan^[@bibr13-2325967120917121]^ (2017)        Determine cost-effective treatment for massive RCTs and pseudoparalysis without osteoarthritis                                  \(1\) RCR (revised once), (2) RCR (conversion to RTSA in case of failure), (3) primary RTSA                 Primary RTSA was cost-effective when utility of RTSA exceeded that of RCR by 0.04 QALYs/y                                                                                                                                                                                                                                                                                                                                           Primary arthroscopic RCR with conversion to RTSA in case of failure most cost-effective strategy
  Huang^[@bibr23-2325967120917121]^ (2017)         Determine cost-effectiveness of single row and double row in arthroscopic RCR                                                   \(1\) Single-row repair, (2) double-row repair                                                              Double-row fixation costlier (\$2134.41 vs \$1654.76, respectively) but more effective than single-row repair (4.073 vs 4.055 QALYs, respectively); ICER of \$26,666.75/QALY for double-row repair                                                                                                                                                                                                                                  Double-row fixation more cost-effective, especially for larger RCTs (3 cm)
  Kang^[@bibr26-2325967120917121]^ (2017)          Compare different treatments for elderly patients with massive irreparable RCTs                                                 \(1\) RTSA, (2) HA, (3) arthroscopic decompression/biceps tenodesis, (4) physical therapy                   RTSA yielded most QALYs with 7.69, but greater benefits came at higher costs; health utility of RTSA was ≤0.72 (QALY, 7.48), or RTSA probability of no complications was ≤0.83 (QALY of 7.48 at cost of \$23,830)                                                                                                                                                                                                                   RTSA considered good value for money compared to other treatments; RTSA most cost-effective treatment in elderly with massive RCTs
  Makhni^[@bibr30-2325967120917121]^ (2016)        Compare cost-effectiveness of arthroscopic RCR to RTSA in patients with symptomatic large/massive RCTs without osteoarthritis   \(1\) Continued nonoperative treatment and/or observation, (2) primary arthroscopic RCR, (3) primary RTSA   Arthroscopic RCR and RTSA superior to nonoperative care (ICER, \$15,500/QALY and \$37,400/QALY, respectively); arthroscopic RCR dominant over primary RTSA; arthroscopic RCR preferred strategy as long as progression rate to end-stage RCT arthropathy \<89%                                                                                                                                                                      Arthroscopic RCR, despite high rates of tendon retearing in large/massive RCTs, may be more cost-effective initial treatment strategy compared to RTSA
  Samuelson^[@bibr54-2325967120917121]^ (2016)     Determine if use of PRP products during arthroscopic RCR is cost-effective                                                      \(1\) With PRP, (2) without PRP                                                                             Cost of RCR with and without PRP was \$6775/QALY and \$6612/QALY, respectively; use of PRP to augment RCR not cost-effective; to achieve willingness-to-pay threshold of \$50,000/QALY, addition of PRP would need to be associated with 9.1% reduction in retear rate                                                                                                                                                              Current use of PRP to augment RCR was not cost-effective
  Carr^[@bibr6-2325967120917121]^ (2015)           Evaluate clinical effectiveness and cost-effectiveness of arthroscopic and open RCR                                             \(1\) Arthroscopic RCR, (2) open RCR                                                                        No differences in mean cost; overall treatment cost at 2 y was £2567 ± £176 for arthroscopic surgery and £2699 ± £149 for open surgery; there was difference in total initial procedure-related costs, with arthroscopic repair being costlier; retear rates not different                                                                                                                                                          In patients \>50 y with degenerative RCTs, no difference in clinical effectiveness or cost-effectiveness between open repair and arthroscopic repair at 2 y
  Mather^[@bibr33-2325967120917121]^ (2013)        Examine value of surgical treatment for full-thickness RCTs from societal perspective                                           \(1\) Different age groups in RCR                                                                           Mean age-weighted total societal savings from RCR compared with nonoperative treatment was \$13,771 over patient's lifetime; savings ranged from \$77,662 (age 30-39 y) to net cost to society of \$11,997 (age 70-79 y); surgical treatment resulted in mean improvement of 0.62 QALYs; estimated lifetime societal savings of \$3.44 billion for ∼250,000 RCR procedures performed yearly in US                                   RCR for full-thickness tears produced net societal cost savings for patients \<61 y and greater QALYs for all patients; RCR was cost-effective for all populations
  Renfree^[@bibr51-2325967120917121]^ (2013)       Prospectively analyze outcomes and costs for primary RTSA                                                                       \(1\) RTSA                                                                                                  Clinical and functional outcomes demonstrated significant improvement; median QALYs improved from 6.56 preoperatively to 7.58 at 2-y follow-up; increase in QALYs calculated from EQ-5D was greater (6.21 to 8.10); mean cost was \$21,536; cost utility at 2 y was \$26,920/QALY by SF-6D and \$16,747/QALY by EQ-5D                                                                                                               EQ-5D and SF-36 (from which the SF-6D is calculated) results demonstrated modestly cost-effective (\<\$50,000/QALY) improvement for RCT arthropathy after primary RTSA
  Coe^[@bibr9-2325967120917121]^ (2012)            Compare cost-effectiveness of RTSA to HA                                                                                        \(1\) RTSA, (2) HA                                                                                          RTSA could be cost-effective strategy for treatment of RCT arthropathy                                                                                                                                                                                                                                                                                                                                                              RTSA could be cost-effective alternative to HA for RCT arthropathy; cost-effectiveness of RTSA depended on health utility gain, complications, and cost of implant
  Genuario^[@bibr16-2325967120917121]^ (2012)      Compare cost-effectiveness of double-row to single-row arthroscopic RCR                                                         \(1\) Double-row repair, (2) single-row repair                                                              ICER for double-row vs single-row arthroscopic RCR was \$571,500 for RCTs \<3 cm and \$460,200 for RCTs of 3 cm; rate of radiographic or symptomatic retears alone had no influence on cost-effectiveness; if increase in cost of double-row repair \<\$287 (small or moderate tears) and \<\$352 (large or massive tears) compared with single-row repair, double-row repair would represent cost-effective surgical alternative   Double-row RCR not cost-effective for any sized RCTs; variability in costs and probability of retears could have profound effect on results and might create environment in which double-row repair becomes more cost-effective option

*^a^*EQ-5D, EuroQol 5 Dimensions index; HA, hemiarthroplasty; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; PRP, platelet-rich plasma; QALY, quality-adjusted life year; RCR, rotator cuff repair; RCT, rotator cuff tear; RTSA, reverse total shoulder arthroplasty; SF-36, 36-Item Short Form Survey; SF-6D, Short Form-6 Dimensions; TSA, total shoulder arthroplasty.

Quality Analysis {#section4-2325967120917121}
----------------

The quality of the studies included in this systematic review was higher compared with studies before 2010. In total, there was one level 1 study, eight level 2 studies, nine level 3 studies, nine level 4 studies, and seven level 5 studies. The eight level 2 studies used complex Markov models and appropriate sensitivity analyses (Monte Carlo simulation, probabilistic sensitivity analysis). Levels of evidence and QHES scores are shown in [Table 2](#table2-2325967120917121){ref-type="table"}. Before 2010, sensitivity analyses and discounting were rarely used in the shoulder literature, whereas these methods have now become common in the included studies.^[@bibr27-2325967120917121]^ [Table 2](#table2-2325967120917121){ref-type="table"} shows the country in which the economic analysis was performed and which models and sensitivity analyses were used. Another important criterion for a high-quality study is whether the aim of the study is clear, specific, and measurable.^[@bibr8-2325967120917121]^ This criterion was fulfilled by all the included studies. The quality of the data on which the models were based was the most difficult aspect to evaluate. In all except 1 presented study,^[@bibr57-2325967120917121]^ expert opinion was included in various amounts, as opposed to data. Therefore, only 1 level 1 study according to the OCEBM criteria could be included in this review. The mean QHES score showed that the overall study quality/methodology was good, with a mean score of 87 (range, 38-100) ([Table 2](#table2-2325967120917121){ref-type="table"}). [Figure 2](#fig2-2325967120917121){ref-type="fig"} presents information regarding how each QHES criterion was met by the 34 studies.

![Breakdown of the overall Quality of Health Economic Studies instrument categories for all 34 included studies. The point value for each criterion is shown in parentheses.](10.1177_2325967120917121-fig2){#fig2-2325967120917121}

Cost Analysis in RCTs {#section5-2325967120917121}
---------------------

In total, there were 13 studies focusing on RCTs. Only 1 study fulfilled the criteria of a level of evidence 2 study, while 7 studies were level 3 ([Table 3](#table3-2325967120917121){ref-type="table"}). The main findings were the following: (1) Although additional factors must be considered, such as available resources and workflow, magnetic resonance imaging is the first-choice imaging strategy based on cost-effectiveness criteria.^[@bibr19-2325967120917121]^ (2) Primary (arthroscopic or open) rotator cuff repair (RCR) is the most cost-effective strategy.^[@bibr13-2325967120917121],[@bibr30-2325967120917121],[@bibr33-2325967120917121]^ In case of failure, conversion to reverse total shoulder arthroplasty (RTSA) seems to be a cost-effective strategy.^[@bibr13-2325967120917121]^ Primarily, RTSA is the most cost-effective treatment option for the elderly (age not specifically defined).^[@bibr26-2325967120917121]^ (3) Platelet-rich plasma as a biological augmentation of RCR seems not to be cost-effective.^[@bibr54-2325967120917121]^ (4) The cost-effectiveness of double-row RCR remains unclear. While it does not seem to be cost-effective for any sized RCTs, the variability in costs and probability of retears might have a profound effect on the results and may create an environment in which double-row repair becomes the more cost-effective option.^[@bibr16-2325967120917121]^ The findings of the five level 4 and 5 studies focusing on the treatment of RCTs can be found in [Table 3](#table3-2325967120917121){ref-type="table"}.

Cost Analysis in Other Abnormalities {#section6-2325967120917121}
------------------------------------

Cost analysis for the treatment of shoulder instability showed the cost-effectiveness of both arthroscopic Bankart repair and the open Latarjet procedure in comparison with nonoperative treatment.^[@bibr11-2325967120917121],[@bibr35-2325967120917121]^ The Latarjet procedure was more cost-effective than revision arthroscopic Bankart repair.^[@bibr29-2325967120917121]^ Total shoulder arthroplasty was found to be the most cost-effective treatment option for glenohumeral arthritis.^[@bibr2-2325967120917121],[@bibr3-2325967120917121],[@bibr34-2325967120917121]^ Regarding proximal humeral fractures, RTSA showed economic advantages over hemiarthroplasty in the elderly (base case of 70 and 72 years) and in complex fracture situations.^[@bibr42-2325967120917121],[@bibr45-2325967120917121]^ A prophylactic administration of local vancomycin powder during arthroplasty was found to be highly cost-effective.^[@bibr22-2325967120917121]^ For the treatment of subacromial impingement, corticosteroid injections plus exercise delivered by a therapist were cost-effective when compared with exercise alone.^[@bibr25-2325967120917121]^ Furthermore, ultrasound-guided injections were found to be the most cost-effective option for the initial steroid-based treatment of adhesive capsulitis.^[@bibr18-2325967120917121]^ A 2019 level 1 study on the cost-effectiveness of surgical treatment for displaced midshaft clavicular fractures showed that surgical treatment was not cost-effective (considering a threshold of €34,000/QALY).^[@bibr57-2325967120917121]^ In patients with professions imposing high loads on the shoulder, however, surgical treatment was described to potentially be more cost-effective compared with nonsurgical treatment.^[@bibr57-2325967120917121]^ Paoli et al^[@bibr46-2325967120917121]^ compared superior labral from anterior to posterior (SLAP) repair, biceps tenodesis, and nonoperative treatment in their cost-effectiveness study on symptomatic SLAP tears. Primary biceps tenodesis was described to be the most cost-effective treatment option among the 3 evaluated procedures for type II SLAP tears in middle-aged patients.^[@bibr46-2325967120917121]^ Detailed findings of the analyzed studies can be found in [Appendix Tables A1](#table5-2325967120917121){ref-type="table"} [](#table6-2325967120917121){ref-type="table"} [](#table7-2325967120917121){ref-type="table"} [](#table8-2325967120917121){ref-type="table"} to [A5](#table9-2325967120917121){ref-type="table"}.

Discussion {#section7-2325967120917121}
==========

Within the scope of this systematic review, 34 full economic analyses concerning shoulder abnormalities were included that have been published more recently than 2010, expanding the older reviews by Kuye et al^[@bibr27-2325967120917121]^ and Teusink et al.^[@bibr58-2325967120917121]^ In contrast to these reviews, only full economic analyses were included. Simple comparisons of costs or cost-minimization studies were disregarded. Most available studies had the perspective of the health care sector. The overall quality of recent studies has significantly improved compared with studies from 2009 and before. The results of cost-effectiveness studies are rarely transferred to daily clinical practice; in most health care systems, medical treatment is customized to the individual patient by doctors, mostly independent of costs. However, exploding costs in health care systems will inevitably lead to an emphasis on more cost-effective therapies in the future.

Representing almost 50% of all included studies, sufficient evidence now exists for the cost-effectiveness of various RCT treatment options. Magnetic resonance imaging was described to be a cost-effective imaging strategy. Primary RCR with conversion to RTSA in case of failure was the most cost-effective strategy. Platelet-rich plasma augmentation of RCR was not cost-effective, and the cost-effectiveness of double-row RCR remained unclear. For displaced proximal humeral fractures (involving the surgical neck), a randomized trial comparing surgical and nonsurgical treatment found no significant between-group differences in quality of life over time.^[@bibr21-2325967120917121]^ For most other abnormalities such as shoulder instability, glenohumeral osteoarthritis, or subacromial impingement, fewer high-quality studies have been published so far.

Despite several high-level studies that recently complemented the available body of literature, uncertainty remains regarding the most cost-effective treatment option for older patients with large or massive RCTs. Makhni et al^[@bibr30-2325967120917121]^ in 2016 analyzed the cost-effectiveness of primary RTSA versus arthroscopic RCR in patients older than 65 years. Although clinical outcomes seemed to be similar in both treatment groups, the authors highlighted the fact that the overall costs were significantly lower in the RCR treatment group, even in cases of postsurgical retears. The authors emphasized this finding by various sensitivity analyses showing that patients with retears would require progression rates to end-stage RCT arthropathy of 89% to justify early RTSA. Similarly, considering a 100% progression rate to RCT arthropathy, the authors calculated a required retear rate of 65% after arthroscopic RCR of RCTs to justify early RTSA. For newer techniques, such as superior capsular reconstruction, no cost-effective analyses are available yet.

Cost analysis on surgical techniques in arthroscopic RCR also revealed varying results. While Genuario et al^[@bibr16-2325967120917121]^ reported in their analysis on the cost-effectiveness of single-row RCR versus double-row RCR that double-row RCR was not cost-effective for any sized RCTs, Huang et al^[@bibr23-2325967120917121]^ found double-row RCR to be more cost-effective than single-row RCR in some cases, especially in larger RCTs. This discrepancy most likely results from the varying underlying costs of surgery that were used for calculations, depending on the health care system. While Huang et al based their calculations on surgery costs of \$1654.76 (single-row RCR) and \$2134.41 (double-row RCR) for primary and revision surgery, respectively, Genuario et al referred to surgery costs being 5 to 7 times higher. This difference strongly influences the ICER per QALY and therefore makes a direct comparison of both studies difficult.

Mather et al^[@bibr33-2325967120917121]^ investigated whether the operative treatment of RCTs is cost-effective from a societal perspective. A complex Markov model was therefore used based on lifelong direct and indirect costs in connection with RCTs. The surgical treatment of RCTs led to cost savings compared with nonoperative treatment depending on the patient's age at the time of treatment (cost savings of \$77,662 in 30- to 39-year-old patients). The model was validated using 1-, 2-, and 3-way sensitivity analyses and Monte Carlo simulations. The response to nonoperative treatment was found to have the biggest impact on the results. If the success rate of nonoperative therapy was increased to 88%, it would be more cost-effective. However, this high success rate is outside of the reported outcome rates for nonoperative therapy. The study by Mather et al^[@bibr33-2325967120917121]^ emphasizes the complexity of these models, which factors are to be included, and how errors can be minimized using simulations. However, the most important aspect is the data on which the model is based, as highlighted by Castagna et al.^[@bibr7-2325967120917121]^ The authors evaluated the subacromial spacer as a new treatment option, but no valid outcome data are available for this treatment method yet.^[@bibr7-2325967120917121]^ Therefore, the model used in the study was based on expert opinion and was prone to errors, regardless of the quality level of the study.^[@bibr7-2325967120917121]^ The performed sensitivity analysis showed that if the success rate of the subacromial spacer is only reduced by 20%, it would no longer be the most cost-effective strategy. This accentuates the immense importance of exact outcome measurements for economic evaluations.^[@bibr48-2325967120917121],[@bibr49-2325967120917121]^

The only study focusing on the prevention of infections after shoulder arthroplasty proved the cost-effectiveness of local vancomycin powder.^[@bibr22-2325967120917121]^ However, these results must be evaluated critically, as only 16 patients were included in a single-center study setup.

Attention should also be paid to the interpretation of the study by Paoli et al,^[@bibr46-2325967120917121]^ who focused on the cost-effectiveness of 3 different treatment options for symptomatic SLAP tears in middle-aged patients (mean age, 40 years). While the authors described primary biceps tenodesis to be the most cost-effective treatment option among the 3 evaluated procedures for type II SLAP tears, it needs to be highlighted that biceps tenotomy was not evaluated.^[@bibr46-2325967120917121]^ This efficient surgical treatment option, however, might also be cost-effective.^[@bibr46-2325967120917121]^

In our study, the QHES score was high (mean, 87), but according to the OCEBM level of evidence, there was only one level 1 study. This crucial difference is based on the fact that the underlying data quality is of utmost importance for OCEBM evidence levels, while the QHES score focuses on study methodology. Thereby, the study quality is rated according to the "best available" source of data. In our opinion, good study quality cannot compensate for poor underlying data, even if they are the "best available." The example shown for Castagna et al^[@bibr7-2325967120917121]^ highlights that fact, and the discrepancy between both tools needs to be considered. In this regard, sensitivity analyses are very valuable.

Compared with other areas in medicine and orthopaedic subspecializations, shoulder surgery was comparable and magnitudes less expensive than, for example, new drugs, in which the ICER could exceed US\$100,000 ([Table 4](#table4-2325967120917121){ref-type="table"}). Therefore, the development and use of suitable quality parameters will be of utmost importance in the future to measure, evaluate, and compare the quality of medical therapies. High-quality studies (level 1) will be required to generate the needed data for economic analyses. An improved outcome (or more inexpensive therapy with the same outcome) must be proven to justify the increased costs and to compare established therapies, especially for new treatments and new medical products. Surgeons today, more than ever, have to incorporate cost-efficiency into their daily treatment strategies. Nevertheless, decisions must, of course, always be based on patient- and disease-specific factors.

###### 

Different Therapy Options for Various Diseases and Their Economic Evaluation*^a^*

![](10.1177_2325967120917121-table4)

  Author (Year)                                  Treatment                                                                                                    ICER
  ---------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------
  Huang^[@bibr23-2325967120917121]^ (2017)       Double-row vs single-row RCR                                                                                 \$26,666.75/QALY gained for double-row repair relative to single-row fixation
  Makhni^[@bibr30-2325967120917121]^ (2016)      RTSA vs arthroscopic RCR for symptomatic large and massive rotator cuff tears                                \$15,500/QALY (arthroscopic RCR vs nonoperative) and \$37,400/QALY (RTSA vs nonoperative)
  Dougherty^[@bibr14-2325967120917121]^ (2013)   Arthroscopic RCR                                                                                             \$13,092/QALY
  Dougherty^[@bibr14-2325967120917121]^ (2013)   Total knee replacement                                                                                       \$18,300/QALY
  Dougherty^[@bibr14-2325967120917121]^ (2013)   Revision total knee replacement                                                                              \$31,341/QALY
  Lubowitz^[@bibr28-2325967120917121]^ (2011)    Arthroscopic ACL reconstruction                                                                              \$10,326/QALY
  Gottlob^[@bibr17-2325967120917121]^ (1999)     ACL reconstruction                                                                                           \$5857/QALY
  Huygens^[@bibr24-2325967120917121]^ (2018)     Transcatheter aortic valve implantation vs standard treatment in inoperable or high-risk operable patients   ICER, €18,421-€120,779
  van Asten^[@bibr59-2325967120917121]^ (2018)   Bevacizumab, ranibizumab, and aflibercept for treatment of age-related macular degeneration                  ICER, \$278,099/QALY when aflibercept used instead of bevacizumab

*^a^*ACL, anterior cruciate ligament; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RCR, rotator cuff repair; RTSA, reverse total shoulder arthroplasty.

Limitations {#section8-2325967120917121}
-----------

This study has several limitations. First, while having tried to assess the available literature as thoroughly as possible by using wide search terms, there is still a chance of having missed available studies. Second, the QHES instrument to assess research methodology represents a potential source of biased scoring. Therefore, two of the authors independently performed the evaluation, and a consensus was reached by a discussion. Third, even though most of the studies are based on good or excellent quality of data, some of the included articles do refer to studies with slightly lower OCEBM levels and QHES scores.

Conclusion {#section9-2325967120917121}
==========

Compared with a 2012 review,^[@bibr27-2325967120917121]^ the study quality improved greatly. The current studies might help decision makers to appropriately and adequately allocate resources. However, further studies are still necessary.
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###### 

Economic Evaluations Concerning Shoulder Instability (n = 3)*^a^*

![](10.1177_2325967120917121-table5)

  Author (Year)                               Purpose                                                                                                                                                                              Groups                                                               Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Conclusions
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Min^[@bibr35-2325967120917121]^ (2018)      Analyze cost-effectiveness of arthroscopic Bankart repair and open Latarjet procedure in primary shoulder instability                                                                \(1\) Arthroscopic Bankart, (2) Latarjet                             Overall recurrence rate of 14% after arthroscopic Bankart and 8% after open Latarjet with equal postoperative health utility states; Monte Carlo simulation showed ICER for Bankart of \$4214 and for Latarjet of \$4681 (*P* \< .001)                                                                                                                                                                                                                                                           Arthroscopic Bankart and open Latarjet highly cost-effective; Bankart more cost-effective because of lower health utility state after failed Latarjet; Latarjet favored in certain circumstances (ie, critical glenoid bone loss); clinical decisions on case-by-case basis
  Makhni^[@bibr29-2325967120917121]^ (2016)   Examine cost-effectiveness of arthroscopic revision instability repair and Latarjet procedure in patients with recurrent instability after initial arthroscopic instability repair   \(1\) Nonoperative, (2) revision arthroscopic repair, (3) Latarjet   Latarjet less expensive than revision arthroscopic repair (\$13,672 vs \$15,287, respectively) with improved clinical outcomes (43.78 vs 36.76 QALYs, respectively); arthroscopic repair and Latarjet cost-effective compared with nonoperative treatment (ICER, 3082 and 1141, respectively); sensitivity analyses indicated that with high rates of stability postoperatively, along with improved clinical outcome scores, revision arthroscopic repair becomes increasingly cost-effective   Latarjet for failed instability repair was cost-effective; lower costs and improved clinical outcomes compared with revision arthroscopic instability repair; treatment algorithm must be formed by surgeon's clinical judgment
  Crall^[@bibr11-2325967120917121]^ (2012)    Compare cost-effectiveness of initial observation to surgery for first-time anterior shoulder dislocation                                                                            \(1\) Primary surgery, (2) nonoperative treatment                    Primary surgery less costly and more effective for 15-y-old boys, 15-y-old girls, and 25-y-old men; for 25-y-old women and 35-y-old men and women, primary surgery more effective but more costly; however, primary surgery was still very cost-effective (cost/QALY, \$25,000); after 1 recurrence, surgery was less costly and more effective for all scenarios                                                                                                                                Primary arthroscopic stabilization was clinically effective and cost-effective for first-time anterior shoulder dislocations; by using willingness-to-pay threshold of \$25,000/QALY, surgery more cost-effective than nonoperative treatment for majority of patients

*^a^*All values are reported as US dollars. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

###### 

Economic Evaluations Concerning Glenohumeral Osteoarthritis (n = 3)*^a^*

![](10.1177_2325967120917121-table6)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)                               Purpose                                                                                                                                       Groups                Results                                                                                                                                                                                                                                                                                                                                                                              Conclusions
  ------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bhat^[@bibr3-2325967120917121]^ (2016)      Characterize costs, as expressed by reimbursements for episodes of acute care, and outcomes associated with arthroplasty for osteoarthritis   \(1\) TSA, (2) HA     Initial HA resulted in average QALY gain of 6.55, and TSA resulted in average QALY gain of 7.96; during lifetime, initial HA led to lifetime revisions of 0.4 per patient, whereas initial TSA led to lifetime revisions of 0.3; during lifetime of 5279 patients, initial HA resulted in \$25,000 per patient-associated direct reimbursements, whereas TSA resulted in \$23,700    On population level, TSA was cost-effective treatment for glenohumeral arthritis in 30- to 50-y-old patients

  Bachman^[@bibr2-2325967120917121]^ (2016)   Compare cost-effectiveness of RTSA to THA                                                                                                     \(1\) RTSA, (2) THA   Cost/QALY was \$3900 for THA and \$11,100 for RTSA; after adjusting model to only include shoulder-specific physical function subscale items, RTSA's QALY improved to 2.8 y, and its cost/QALY decreased to \$8100                                                                                                                                                                   Based on industry accepted standards, cost/QALY estimates supported cost-effectiveness of both RTSA and THA; although THA remained "gold standard" in improving quality of life among arthroplasty procedures, cost/QALY estimates supported growing use of RTSA to improve quality of life

  Mather^[@bibr34-2325967120917121]^\         Compare cost-effectiveness of TSA to HA                                                                                                       \(1\) TSA, (2) HA     HA had lower number of average QALYs gained at higher average cost to society and was therefore dominated by TSA in glenohumeral osteoarthritis; cost-effectiveness ratio for TSA and HA was \$957/QALY and \$1194/QALY, respectively; sensitivity analysis showed that if utility of TSA is equal to HA, or revision rate is lower than HA, TSA continues to be dominant strategy   TSA with cemented glenoid was cost-effective, with greater utility for patient at lower overall cost to payer; from perspectives of patient and payer, TSA was preferred for certain populations
  (2010)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*^a^*All values are reported as US dollars. HA, hemiarthroplasty; QALY, quality-adjusted life year; RTSA, reverse total shoulder arthroplasty; THA, total hip arthroplasty; TSA, total shoulder arthroplasty.

###### 

Economic Evaluations Concerning Proximal Humeral Fractures (n = 4)*^a^*

![](10.1177_2325967120917121-table7)

  Author (Year)                                                                                                                            Purpose                                                                                               Groups                                 Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Conclusions
  ---------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Osterhoff^[@bibr45-2325967120917121]^ (2017)                                                                                             Compare cost-effectiveness of RTSA to HA in management of complex proximal humeral fractures          \(1\) RTSA, (2) HA                     Incremental cost/QALY gained for RTSA was Can\$13,679; 1-way sensitivity analysis showed model to be sensitive to RTSA implant and procedural costs; probabilistic sensitivity analysis showed that 92.6% of model simulations favored RTSA                                                                                                                                                                                                                                                 RTSA for treatment of complex proximal humeral fractures in elderly patients was economically preferred; ICER of RTSA was well below standard willingness-to-pay thresholds; cost-effectiveness similar to other highly successful orthopaedic strategies (ie, THA)
  Nwachukwu^[@bibr42-2325967120917121]^ (2016)                                                                                             Assess cost-effectiveness of nonoperative care, HA, and RTSA for complex proximal humeral fractures   \(1\) Nonoperative, (2) HA, (3) RTSA   From payer perspective, ICER of RTSA was \$8100/QALY; HA was eliminated from payer analysis as cost-ineffective strategy; from hospital perspective, HA was not cost-ineffective, and ICER was \$36,700/QALY, with RTSA providing incremental effectiveness at \$57,400/QALY; RTSA was optimal in 61% and 54% of payer and hospital probabilistic sensitivity analyses, respectively; preferred strategy depended on associated QALY gains, primary RTSA cost, and failure rates for RTSA   RTSA could be cost-effective in surgery of complex proximal humeral fractures; HA also cost-effective depending on perspective (cost-ineffective for payer but cost-effective for hospital); opportunities for increased cost-sharing strategies to alleviate cost burden on hospitals
  Corbacho^[@bibr10-2325967120917121]^ (2016)/Handoll^[@bibr20-2325967120917121]^ (2015)/Handoll^[@bibr21-2325967120917121]^ (2017)*^b^*   Compare surgery with no surgery for displaced proximal humeral fractures                              \(1\) Surgery, (2) no surgery          Surgery showed mean greater costs and marginally lower QALYs than nonsurgery; surgery cost £1758 more per patient (95% CI, £1126 to £2389); total QALYs for surgery were smaller than nonsurgery (--0.0101 \[95% CI, --0.13 to 0.11\]); probability of surgery being cost-effective was \<10%, given current NICE willingness-to-pay threshold of £20,000 for additional QALY; results were robust to sensitivity analyses                                                                  Current surgical treatment was not cost-effective for majority of displaced fractures of proximal humerus involving surgical neck in NHS

*^a^*All values are reported as US dollars unless otherwise specified. HA, hemiarthroplasty; ICER, incremental cost-effectiveness ratio; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; QALY, quality-adjusted life year; RTSA, reverse total shoulder arthroplasty; THA, total hip arthroplasty.

*^b^*All 3 studies were related to the PROFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial. The two Handoll et al studies were considered a single study for the purposes of this review.

###### 

Economic Evaluations Concerning Subacromial Impingement (n = 4)*^a^*

![](10.1177_2325967120917121-table8)

  Author (Year)                                   Purpose                                                                                                                                                                                                Groups                                                                                  Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Conclusions
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rombach^[@bibr52-2325967120917121]^ (2019)      Assess cost-effectiveness of ASD compared with arthroscopic surgery only and with no treatment                                                                                                         \(1\) ASD, (2) arthroscopic surgery only, (3) no treatment                              Statistically significant differences in cumulative QALYs and costs were found at 6 and 12 mo for ASD compared with no treatment; probabilities of ASD being cost-effective compared with no treatment at willingness-to-pay threshold of £20,000/QALY were ∼0% at 6 mo and ∼50% at 1 y, with probabilities potentially increasing at 2 y                                                                                                                                                                                                                                       No evidence that ASD was cost-effective during 1-y follow-up period; it could be cost-effective in long term
  Arias-Buria^[@bibr1-2325967120917121]^ (2018)   Evaluate cost-effectiveness of addition of TrP-DN to exercise program in subacromial pain syndrome                                                                                                     \(1\) Exercise alone, (2) exercise plus TrP-DN                                          Those in exercise group made more visits to medical doctors and underwent greater number of other treatments; combination of exercise plus TrP-DN was less costly (mean difference in cost/patient, €517.34); incremental QALYs showed greater benefit for exercise plus TrP-DN; inclusion of TrP-DN into exercise program was more likely to be cost-effective than exercise program alone                                                                                                                                                                                     From cost-benefit perspective, inclusion of TrP-DN into multimodal management of patients with subacromial pain syndrome should be considered
  Marks^[@bibr31-2325967120917121]^ (2016)        Compare clinical effectiveness and cost-effectiveness of corticosteroid injection for shoulder pain by physical therapist or orthopaedic surgeon                                                       \(1\) Orthopaedic surgeon, (2) physical therapist                                       64 participants randomized (33 for physical therapist, 31 for orthopaedic surgeon); no significant differences in baseline characteristics between groups; noninferiority of injection by physical therapist demonstrated from total SPADI scores at 6 and 12 wk (upper limit of 95% CI, 13.34 and 7.17 at 6 and 12 wk, respectively); no statistically significant differences between groups on any outcome measures at 6 or 12 wk; from perspective of health funder, physical therapist was less expensive                                                                  Corticosteroid injection for shoulder pain, provided by qualified physical therapist, was clinically effective and less expensive; policy makers and service providers should consider implementing this model of care
  Jowett^[@bibr25-2325967120917121]^ (2013)       Analyze cost-effectiveness of subacromial corticosteroid injection with exercise compared with exercise alone in patients with moderate to severe shoulder pain and subacromial impingement syndrome   \(1\) Subacromial corticosteroid injection combined with exercise, (2) exercise alone   Mean NHS cost/patient (£255 vs £297, respectively) and overall health care cost (£261 vs £318, respectively) were lower in injection plus exercise arm, with no statistical significance; total QALYs gained were very similar in both arms (0.3514 vs 0.3494, respectively), although slightly higher in injection plus exercise arm, indicating that injection plus exercise may be dominant treatment option; at willingness-to-pay threshold of £20,000 per additional QALY gained, there was 61% probability that injection plus exercise was most cost-effective option   Injection plus exercise delivered by therapists was cost-effective, with lower health care costs and less time off work

*^a^*ASD, arthroscopic subacromial decompression; NHS, National Health Service; QALY, quality-adjusted life year; SPADI, Shoulder Pain and Disability Index; TrP-DN, trigger point dry needling.

###### 

Remaining Economic Evaluations (n = 7)*^a^*

![](10.1177_2325967120917121-table9)

  Author (Year)                                    Purpose                                                                                                                                                              Groups                                                                             Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Conclusions
  ------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sorensen^[@bibr57-2325967120917121]^ (2020)      Investigate cost utility of plate fixation compared with nonoperative treatment of displaced midshaft clavicular fractures                                           \(1\) Plate fixation, (2) nonoperative treatment                                   Plate fixation was associated with larger QALY gain and higher cost; ICER was estimated to be €182,306/QALY from health sector perspective and €186,158/QALY from societal perspective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Plate fixation was not cost-effective when considering threshold of €34,000/QALY; however, for subgroup of patients with high-loading shoulder professions, plate fixation might be cost-effective
  Gyftopoulos^[@bibr18-2325967120917121]^ (2018)   Determine cost-effectiveness of landmark-based and imaging-guided intra-articular steroid injections for initial treatment of adhesive capsulitis                    \(1\) Landmark based, (2) imaging guided                                           Ultrasound-guided injections dominant for base case (least expensive \[\$1280\] and most effective \[0.4096 QALYs\]); model sensitive to probabilities of injecting steroid into joint (blind, ultrasound-guided, fluoroscopy-guided) and costs of ultrasound-guided and blind techniques; 2-way sensitivity analyses showed ultrasound-guided injections favored over blind and fluoroscopy-guided injections over range of reasonable probabilities and costs; probabilistic sensitivity analysis showed that ultrasound-guided injections were cost-effective in 44%, 34% for blind injections, and 22% for fluoroscopy-guided injections and over wide range of willingness-to-pay thresholds                                                                                                                                                 Ultrasound-guided injection was most cost-effective option; blind and fluoroscopy-guided injections could also be cost-effective when performed by clinician likely to accurately administer medication into correct location
  Paoli^[@bibr46-2325967120917121]^ (2018)         Evaluate cost-effectiveness of nonoperative management, primary SLAP repair, and primary biceps tenodesis for treatment of symptomatic isolated type II SLAP tears   \(1\) SLAP repair, (2) biceps tenodesis, (3) nonoperative treatment                Primary biceps tenodesis compared with SLAP repair conferred increased effectiveness of 0.06 QALYs, with cost savings of \$1766; compared with nonoperative treatment, both biceps tenodesis and SLAP repair were cost-effective; sensitivity analysis showed that biceps tenodesis was preferred strategy in most simulations (52%); however, for SLAP repair to become cost-effective over biceps tenodesis, its probability of failure would have to be \<2.7% or cost of biceps tenodesis would have to be \>\$14,644                                                                                                                                                                                                                                                                                                                         Compared with primary SLAP repair and nonoperative treatment, primary biceps tenodesis was most cost-effective treatment strategy in middle-aged patients
  Hatch^[@bibr22-2325967120917121]^ (2017)         Assess vancomycin for preventing shoulder replacement infections                                                                                                     \(1\) Vancomycin, (2) no vancomycin                                                Efficacy of vancomycin (ARR) evaluated at different unit costs, baseline infection rates, and average costs of treating infection; vancomycin was cost-effective if initial infection rate decreased by 0.04% (ARR); using current costs of vancomycin in literature (range, \$2.50/1000 mg to \$44/1000 mg), vancomycin was cost-effective with ARR range of 0.01% at cost of \$2.50/1000 mg to 0.19% at \$44/1000 mg; baseline infection rates did not influence ARR obtained at any specific cost of vancomycin or cost of treating infection                                                                                                                                                                                                                                                                                                  Breakeven equation to assess efficacy of prophylactic antibiotics during shoulder surgery; prophylactic administration of local vancomycin powder during shoulder arthroplasty was highly cost-effective
  Scott^[@bibr55-2325967120917121]^ (2015)         Evaluate if economic savings are realized when procedures are performed by high-volume compared with low-volume providers                                            \(1\) High-, (2) medium-, (3) low-volume providers for ACL surgery, RCR, and TSA   Cost/case attributable to adverse outcomes for ACL reconstruction was \$496, \$781, and \$868 for high-, medium-, and low-volume providers; for RCR, it was \$523, \$640, and \$872, respectively; for TSA, it was \$1692, \$1876, and \$2021, respectively; sensitivity analysis showed that 50% increase in number of these 3 procedures performed by high-volume surgeons could save health care system \$23.1 million; if all procedures were performed by high-volume surgeons, it could save \$72 million                                                                                                                                                                                                                                                                                                                                   Higher provider volumes did convey substantial societal economic benefits; policies to incentivize and facilitate greater portion of procedures being performed by high-volume surgeons might increase efficiency of resource utilization in health care delivery
  Dattani^[@bibr12-2325967120917121]^ (2013)       Examine shoulder stiffness treated with ACR alone and ACR with ASD                                                                                                   \(1\) ACR, (2) ACR and ASD                                                         Of 100 patients, 68 underwent ACR alone, and 32 underwent ACR with ASD; ACR showed highly significant improvement in range of movement and functional outcomes (OSS and EQ-5D); mean cost/QALY for ACR and ACR with ASD was £2563 and £3189, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ACR was cost-effective in restoring relatively normal function and health-related quality of life in most patients with contracture of shoulder within 6 mo after surgery; beneficial effects not related to duration of symptoms
  Pearson^[@bibr47-2325967120917121]^ (2010)       Determine cost-effectiveness of ORIF of displaced midshaft clavicular fractures                                                                                      \(1\) Clavicle ORIF, (2) nonoperative treatment                                    Base case cost per QALY gained for ORIF was \$65,000; cost-effectiveness improved to \$28,150 per QALY gained when benefit from ORIF was assumed to be permanent, with cost per QALY gained \<\$50,000 when functional advantage persisted for ≥9.3 y; in other sensitivity analyses, cost per QALY gained for ORIF \<\$50,000 when ORIF cost \<\$10,465 (base case cost, \$13,668) or long-term utility difference between nonoperative treatment and ORIF was \>0.034 (base case difference, 0.014); short-term disutility associated with fracture healing also affected cost-effectiveness, with cost per QALY gained for ORIF \<\$50,000 when utility of fracture treated nonoperatively before union was \<0.617 (base case utility, 0.706) or when nonoperative treatment increased time to union by 20 wk (base case difference, 12 wk)   Cost-effectiveness of ORIF after acute clavicular fractures depended on durability of functional advantage for ORIF compared with nonoperative treatment; when functional benefits persisted for \>9 y, ORIF had favorable value compared with many accepted health interventions

*^a^*All values are reported as US dollars unless otherwise specified. ACL, anterior cruciate ligament; ACR, arthroscopic capsular release; ARR, absolute risk reduction; ASD, arthroscopic subacromial decompression; EQ-5D, EuroQol 5 Dimensions index; ICER, incremental cost-effectiveness ratio; ORIF, open reduction internal fixation; OSS, Oxford Shoulder Score; QALY, quality-adjusted life year; RCR, rotator cuff repair; SLAP, superior labral from anterior to posterior; TSA, total shoulder arthroplasty.
